Company: NKLR
Filing Date: 2025-11-10
Form Type: S-1
Source: 0001213900-25-108246
Chunk: 113

Company: Terra Innovatum Global N.V.
Filing Date: 2025-11-10
Form: S-1
Chunk 113
---
 Radiological Containment For Small And Micro Nuclear Reactors               |     | 4/20/2025 |     | 4/20/2026   |     | 4/20/2046  |
| Radioisotopes Production                                                                   
 with Nuclear Micro-Reactor                                                                 |     | 4/20/2025 |     | 4/20/2026   |     | 4/20/2046  |

<div align='center'>61</div>

We also engage with international and local
regulatory bodies and existing frameworks to safeguard our innovations across various jurisdictions. However, certain countries where
our reactor components may be manufactured or where our reactor systems may be deployed may offer less robust protection for nuclear
intellectual property compared to the United States or European Union regulatory environments.

Our intellectual property strategy employs
a systematic assessment framework considering:

| — | Critical                                                           
 component manufacturing locations and supply chain considerations; |

| — | Strategic                                                                    
 nuclear technology development pathways across different regulatory regimes; |

| — | Nuclear-specific                                                                     
 intellectual property enforcement mechanisms in target deployment jurisdictions; and |

| — | Commercial                                                                                
 significance relative to established and emerging competitors in specific nuclear markets 
 and regions.                                                                              |

We plan to establish licensing agreements for
certain specialized nuclear technologies from third-party developers and anticipate continued expansion of such arrangements as our reactor
deployment roadmap advances.

Manufacturing and supply chain

We implement a fabless and contract manufacturing
strategy, and expect to contract with key suppliers for all phases of the manufacturing process. We leverage the expertise of industry-leading
suppliers that comply with nuclear quality assurance standards — including 10 CFR 50 Appendix B — in
areas including fabrication, assembly, quality control, reliability testing, and licensing. This approach allows Terra Innovatum
to avoid the significant costs and risks associated with owning and operating manufacturing facilities while enabling scalability and
rapid response to markets changing conditions.

While we plan to directly procure certain critical
raw materials used in our products, such as moderators, fuel, and specialized components, our suppliers are expected to manage procurement
for most other components. This enables us to focus our resources on product design, licensing, quality assurance, marketing, and customer
engagement.

To anticipate high growth periods, we may place
non-cancellable inventory orders for certain components ahead of historical lead times, pay premiums, or provide deposits to secure future
supply and manufacturing capacity.

Our supply chain is positioned for deployment,
with manufacturing risks mitigated through qualification testing of key components